Skip to main content Skip to main navigation menu Skip to site footer

The relationship between the difference neutrophil to lymphocyte ratio before and after anthracycline-based neoadjuvant chemotherapy with clinical response in locally advanced breast cancer

  • Hadian Rahman ,
  • Iskandar Ali ,
  • Dwi Hari Susilo ,


Link of Video Abstract:

: The difference in the Neutrophil-to-Lymphocyte Ratio (NLR) before and after chemotherapy, which is commonly called the delta NLR, is thought to be a better predictive factor than pre-chemotherapy NLR or post-chemotherapy NLR in breast cancer patients.

Methods: We analyzed 130 locally advanced breast cancer (LABC) patients who received anthracycline-based neoadjuvant chemotherapy (NACT) at Dr. Soetomo General Hospital Surabaya from January 2017 – December 2021.

Results: Out of 130 patients, 91 (70.0%) responded to chemotherapy. Bivariate analysis showed a significant relationship between delta NLR and chemotherapy response (p = 0.002). Patients with delta NLR < 0 achieved a significantly higher rate of clinical response to NACT compared to those with delta NLR ≥ 0 (OR: 4.67, 95% CI: 1.69 – 12.85, p: 0.003)

Conclusion: LABC patients with delta NLR < 0 have better clinical response to anthracycline-based NACT than those with delta NLR ≥ 0.


  1. International Agency for Research on Cancer (IARC). Breast - Global Cancer Observatory. Globocan. 2020;419:1-2.
  2. International Agency for Research on Cancer (IARC). Indonesia - Global Cancer Observatory. Globocan. 2020;858:1-2.
  3. Manuaba I, Azamris, Pieter J, Lukitto P, Reksoprawiro S, Aryandono T. Panduan Penatalaksanaan Kanker Solid PERABOI 2010. (Manuaba I, ed.). Sagung Seto; 2010.
  4. Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017;28(1):16-33. doi:10.1093/annonc/mdw544
  5. Gradishar WJ, Abraham J, Aft R, et al. NCCN Guidelines Version 3.2019 Breast Cancer NCCN Guidelines Panel Disclosures. Published online 2019.
  6. American Joint Committee on Cancer. Cancer Staging Manual. 8th ed. (Amin MB, Edge SB, Greene FL, Schilsky RL, Gaspar LE, Washington MK, eds.). American College of Surgeons; 2018.
  7. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thu B. Strategies for subtypes — dealing with the diversity of breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. 2011;(June):1736-1747. doi:10.1093/annonc/mdr304
  8. Vries E De, Schwartz LH, Litie S, et al. ScienceDirect RECIST 1 . 1 d Update and clarification : From the RECIST committee. 2016;(March):1-6. doi:10.1016/j.ejca.2016.03.081
  9. Wang FEN, Liu Z, Xia Y, Zhou C, Shen X. Changes in neutrophil/lymphocyte and platelet / lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. Published online 2015:3411-3418. doi:10.3892/ol.2015.3783
  10. Li Z, Zhao R, Cui Y, Zhou Y, Wu X. The dynamic change of neutrophil to lymphocyte ratio can predict clinical outcome in stage I-III colon cancer. 2018;(February):1-8. doi:10.3978/j.issn.2078-6891.2015.080
  11. Hyder J, Boggs DH, Hanna A, Suntharalingam M, Chuong MD. Changes in neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios during chemoradiation predict for survival and pathologic complete response in trimodality esophageal cancer patients. 2015;7(2):189-195.
  12. Kim Y, Lee I, Chung YS, et al. Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obs Gynecol Sci. 2018;61(2):227-234.
  13. Dan J, Tan J, Huang J, et al. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer. 2020;(0123456789). doi:10.1007/s12282-020-01096-x
  14. American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta Am Cancer Soc Inc. Published online 2020:1-43.
  15. Azhar Y, Agustina H, Abdurachman M, Achmad D. Breast Cancer in West Java : Where Do We Stand and Go ? 2020;14(September):91-96.
  16. Gondhowiardjo S, Soediro R, Jayalie VF, et al. Multicenter Management of Breast Cancer in Indonesia : Ten Years of Experience Manajemen Multisenter Kanker Payudara di Indonesia : 2020;8(2). doi:10.23886/ejki.8.11020
  17. Anwar SL, Harahap WA, Cahyono R, Avanti WS, Budiman HY, Aryandono T. Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression : A retrospective cohort study. Ann Med Surg. 2021;63(1):102144. 2021;63(1):102144. doi:10.1016/j.amsu.2021.01.092
  18. Hartaningsih NMD, Sudarsa IW. Kanker payudara pada wanita usia muda di bagian bedah onkologi rumah sakit pusat Sanglah Denpasar tahun 2002 - 2012. Published online 2013.
  19. Loibl S, Jackisch C, Lederer B, et al. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat. 2015;152(2):377-387. doi:10.1007/s10549-015-3479-z
  20. Nasional IPDBK dan JK. Profil Kanker Timja Payudara RS Kanker Dharmais. Published online 2020.
  21. Delcea C, Buzea CA, Dan GA. The neutrophil to lymphocyte ratio in heart failure : a comprehensive review. Rom J Intern Med. 2019;57(4):296-314.
  22. Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Katafuchi E, Seki M. High neutrophil / lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease. Ren Fail. 2019;41(1):238-243. doi:10.1080/0886022X.2019.1595645
  23. Hussain M, Zafar M, Babar M, Akhtar L, Hussain MS. Neutrophil lymphocyte ratio ( NLR ): A well assessment tool of glycemic control in Type-2 diabetic patients. 2017;33(6):1366-1370.
  24. Kao YJT, Peng T, Chen W, Chang YLP, Wu L. Neutrophil to lymphocyte ratio as predictor for incident hypertension : a 9-year cohort study in Taiwan. Hypertens Res. Published online 2019:1209-1214. doi:10.1038/s41440-019-0245-3
  25. Bedel C, Korkut M, Armagan HH. International Immunopharmacology NLR , d-NLR and PLR can be affected by many factors. Int Immunopharmacol. 2021;90(October 2020):107154. doi:10.1016/j.intimp.2020.107154
  26. Prasetyo YE, Bahrun U, Pakasi RD. Angka banding neutrofil/limfosit di karsinoma payudara. Indones J Clin Pathol Med Lab. 2015;21(2).
  27. Ariful MI, Adi-kusumo F, Hilda S. Characteristics of breast cancer patients at dr . Sardjito Hospital for early anticipation of neutropenia : Cross-sectional study. Ann Med Surg. 2022;73(October 2021):103189. doi:10.1016/j.amsu.2021.103189
  28. Asri R, Pontoh V, Merung M. Neutrofil Darah Tepi pada Pasien Kanker Payudara Stadium Lanjut Sebelum dan Sesudah Dilakukan Tindakan. J BIOMEDIK. 2019;11(1).
  29. Sinaga ES, Ahmad RA, Shivalli S, Hutajulu SH. Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia. 2018;8688:1-9. doi:10.11604/pamj.2018.31.163.17284
  30. Kaufmann M, Von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508-1516. doi:10.1245/s10434-011-2108-2
  31. Rehman B, Shakeel O, Rehman S, et al. Predictive factors involved in determining response to neoadjuvant chemotherapy in high grade serous ovarian cancer and impact of response on 5 years disease free survival and overall survival. Pakistan J Med Heal Sci. 2020;14(3):638-643. doi:10.31487/j.COR.2020.08.05
  32. Ryspayeva D, Lyashenko A, Dosenko I, et al. Predictive factors of pathological response to neoadjuvant chemotherapy in patients with breast cancer. 2020;25(1):168-175.
  33. Karam D, Kumar S, Sudarsan R, Prasad M. Reintroducing FAC regimen as Neoadjuvant Chemotherapy in Clinically Node Positive Locally Advanced Breast Cancer. Oncology. 2017;6(4):233-234.
  34. Stamatovic L, Susnjar S, Gavrilovic D, Minic I, Ursulovic T, Dzodic R. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients. J BUON. 2018;23(5):1273-1280. doi:10.1016/s0960-9776(17)30266-7
  35. Devi DGAP, Purwanto H, Sandhika W. Changes in Ki67 expression and clinical response to neoadjuvant chemotherapy in locally advanced breast cancer (LABC). Bali Med J. 2021;10(3). doi: 10.15562/bmj.v10i3.2700

How to Cite

Rahman, H., Iskandar Ali, & Dwi Hari Susilo. (2023). The relationship between the difference neutrophil to lymphocyte ratio before and after anthracycline-based neoadjuvant chemotherapy with clinical response in locally advanced breast cancer. Bali Medical Journal, 12(3), 3088–3092.




Search Panel